CONFIRM vs BRIGHT

CONFIRM trial was published in

• Diabetes Obesity Metabolism in 2019

• Diabetes Care in 2018

• None of above

BRIGHT Trial was published in

• Diabetes Obesity Metabolism in 2019

• Diabetes Care 2018

• None of above

CONFIRM was a multicenter, open-label, active-controlled, two-arm, parallel-group, 24-week, noninferiority study in insulin-naive patients with uncontrolled type 2 diabetes

• TRUE

• FALSE

• NOT SURE

IGlar U100 was approved by FDA in

• 1990

• 1995

• 2000

• 2005

IGlar U300 was approved by FDA in

• 2000

• 2005

• 2010

• 2015

CV safety of Degludec was established from CVOT

• BEGIN

• ORIGIN

• DEVOTE

Regarding CONFIRM trial;

select all that applies

• Non-interventional comparative effectiveness study

• The primary endpoint, change in HbA1c from baseline to 180 days of follow-up

• Data concerning 405 patients were analysed

• Exploratory endpoints were change in body mass index (BMI) and

  mean end-of-study (EOS) basal insulin doses (units/day)

The CONFIRM trial showed significant reduction in ___ in the IGlar U300 arm

• HbA1c

• Insulin dose

• Hypoglycemia

• All of above

• None of above

BRIGHT trial showed ___ of IGlar vs IDeg in glycemic control

• Superiority

• Inferiority

• Non Inferiority

• Non Equivalence

What is confidence interval?

Evaluate responses using AI:

OFF